Beiersdorf AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDRFF research report →
Price Chart
About the company
Beiersdorf AG is a global producer and distributor of consumer products, operating across continents including Europe, the Americas, Africa, Asia, and Australia. Its operations are divided into two primary divisions: Consumer Business and Tesa Business. The Consumer division specializes in skin and body care items.
- CEO
- Vincent Warnery
- IPO
- 2010
- Employees
- 22,399
- HQ
- Hamburg, HA, DE
Get TickerSpark's AI analysis on BDRFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.12B
- P/E
- 18.38
- Fwd P/E
- 24.00
- PEG
- 0.32
- P/S
- 1.79
- P/B
- 1.91
- EV/EBITDA
- 10.73
- Div Yield
- 1.27%
- Gross Margin
- 57.13%
- Op Margin
- 12.13%
- Net Margin
- 9.75%
- ROE
- 10.66%
- ROIC
- 8.59%
Latest fiscal year · YoY change
- Revenue
- $9.85B-0.0%
- Gross Profit
- $5.68B-1.4%
- Op Income
- $1.35B
- Net Income
- $938.65M+2.9%
- EPS
- $4.25+5.5%
- OCF Growth
- -33.3%
- FCF Growth
- -53.0%
- 52W High
- $122.38
- 52W Low
- $79.77
- 50D MA
- $88.13
- 200D MA
- $96.49
- Beta
- 0.49
- RSI (14)
- 71
- Avg Volume
- 650
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Beiersdorf’s first half was hit by a weak NIVEA, but Derma, La Prairie and Tesa improved, and management is now launching an 18-month NIVEA turnaround with higher consumer investment.· August 5, 2026
- Group H1 net sales were EUR 4.952 billion, with organic sales down 3.5%; Consumer organic sales fell 4.0% to EUR 4.113 billion and Tesa was down 0.9% organically to EUR 839 million.
- Consumer EBIT was EUR 632 million with a 15.4% margin; group EBIT excluding special factors was EUR 768 million with a 15.5% margin, while EPS rose to EUR 2.52.
- NIVEA remained the main drag, with organic sales down 6.7% in Q2 and 6.8% in H1, while Derma grew 7.8% in H1 and La Prairie returned to Q2 growth.
- Management launched a decisive 18-month NIVEA turnaround, including a EUR 100 million increase in consumer-facing investment in the second half.
- Full-year guidance was cut for Consumer to a low single-digit organic sales decline and at least 11% EBIT margin; group guidance is now a low single-digit organic decline and at least 11.8% EBIT margin.
Group net sales were EUR 4.952 billion in H1 2026, with organic sales down 3.5%. Consumer net sales were EUR 4.113 billion, down 4.0% organically and 5.0% nominally, with EBIT of EUR 632 million and a 15.4% margin, down 60 basis points year over year. Consumer gross margin fell to 61.0% from 62.0% in H1 2025. Tesa net sales were EUR 839 million, down 0.9% organically and 2.1% nominally, with EBIT of EUR 136 million. Group gross margin was 58.3%, down 110 basis points; EBIT excluding special factors was EUR 768 million at a 15.5% margin; profit after tax was EUR 558 million and EPS was EUR 2.52. For 2026, management now expects Consumer organic sales to decline low single digits, Consumer EBIT margin to be at least 11%, Tesa organic sales to be flat to slightly growing with EBIT margin slightly below prior year, and group organic sales to decline low single digits with EBIT margin at least 11.8%.
Vincent Warnery said the first half was pressured by a volatile market, geopolitical disruption in the Middle East, and especially NIVEA underperformance. He framed the response as a deliberate reset: broader portfolio support for NIVEA, more accessible face care, more local execution, and a sharper consumer-facing investment push, with a clear goal of returning to profitable growth from 2028. His tone was candid but confident, repeatedly saying the team has learned from the last 6 months and is “pretty confident” in the new path, while acknowledging it will take time and disciplined execution.
Astrid Hermann walked through the financials and emphasized margin pressure from gross margin weakness, higher raw material costs, lower volume, and FX. Consumer gross margin fell 100 basis points to 61.0%, group gross margin fell 110 basis points to 58.3%, and marketing and selling expenses rose to 34.8% of sales, partly because the company is prioritizing consumer-facing spend; R&D also rose to 3.8% of sales, while G&A was reduced through cost discipline. She also highlighted that special factors were only EUR 8 million versus EUR 20 million a year ago, profit after tax was broadly stable at EUR 558 million, and EPS increased to EUR 2.52 supported by the share buyback. On capital allocation, management reaffirmed the EUR 750 million buyback commitment and said cash generation remains tied to a midterm free-cash-flow target of at least 50% of EBITDA.
Questions centered on whether Beiersdorf is overspending to fix NIVEA, whether the brand has lost relevance, how much of the sell-in/sell-out gap is due to retailer conflicts, and whether the company needs a broader operating-model or portfolio overhaul. Management said the NIVEA issue is mainly about rebalancing the portfolio, speeding innovation, and restoring accessibility, not a fundamental operating-model failure, while acknowledging they need to be more decentralized locally and less dependent on Hamburg for every decision. On retailer disputes, management said about 30% of the sell-in/sell-out gap is due to conflicts, and that deals now cover 92% of the European business, with no expectation of further disruptions or meaningful restocking. They also said Coppertone is being focused on sports and profitability rather than growth, and that the company does still want to acquire new brands, especially to reduce dependence on NIVEA over time.
The positive case is that Beiersdorf still has clear growth engines: Derma grew 7.8% in H1, La Prairie improved in Q2, Health Care grew 6.2% in Q2, and Tesa returned to Q2 growth. Management pointed to strong pipeline momentum in the second half, including Aquaphor Body, Face Plus, Swiss Pristine, and more Eucerin initiatives, plus the belief that NIVEA sell-out is already improving and should align with sell-in by year-end.
The main risk is that NIVEA is still declining and management is only now launching an 18-month turnaround after several weak quarters. The company is also accepting a lower-margin year: gross margin fell, consumer EBIT margin is guided to at least 11% versus 13.6% last year, and management warned that higher input costs, negative mix from rebalancing, and higher consumer investment will pressure 2026 profitability. Retailer disputes are not fully behind them, and management said some headwinds may continue into the next quarters.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 36.5%
- Shares Outstanding
- 218.07M
- Float Shares
- 79.62M
Held by 3 ETFs
Biggest fund positions in BDRFF by dollar value.
Our BDRFF coverage
Recent articles, reports, and earnings notes.
No research on BDRFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BDRFF report →Nivea-maker Beiersdorf cuts sales guidance for 2026
reuters.com · Aug 3
Beiersdorf Aktiengesellschaft (BDRFY) Q1 2026 Earnings Call Transcript
seekingalpha.com · Apr 21
Beiersdorf Aktiengesellschaft (OTCMKTS:BDRFF) Receives Average Recommendation of “Reduce” from Brokerages
defenseworld.net · Apr 3
Beiersdorf: Taking Advantage Of The Sell-Off To Go Long
seekingalpha.com · Mar 29
Beiersdorf Aktiengesellschaft (BDRFY) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 3
Beiersdorf Shares Fall on Sluggish 2026 Outlook
wsj.com · Mar 3
Beiersdorf: Three Catalysts For The Year Ahead
seekingalpha.com · Oct 25
Beiersdorf Aktiengesellschaft (BDRFY) Q3 2025 Earnings Call Transcript
seekingalpha.com · Oct 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.